DOCSLIB.ORG

Photodynamic Therapy for Cholangiocarcinoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Photodynamic Therapy for Cholangiocarcinoma Gut and Liver, Vol. 4, Suppl. 1, September 2010, pp. S62-66 REVIEW Photodynamic Therapy for Cholangiocarcinoma Jayant P. Talreja and Michel Kahaleh Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA, USA Cholangiocarcinoma is the primary malignancy arising The average 5-year survival rate of patients with chol- from the biliary epithelium, and it presents as jaun- angiocarcinoma is 5-10%.10 The incidence of cholangio- dice, cholestasis, and cholangitis. Over 50 percent of carcinoma is increasing11 and is currently thought to be patients present with advanced-stage disease, and the one to two cases per 100,000 patients in the United prognosis is poor with the survival measured in months States, with the majority of patients being predominantly even after biliary decompression. Palliative manage- 10 male and older than 65 years of age. The only hope for ment has become the standard of care for unresect- cure is surgical resection. Even after curative resection, able disease, and this involves an endoscopic ap- the 5-year survival rate is only 30-40%.12-14 Unfortunately, proach. Photodynamic therapy (PDT) involves the ad- ministration of a photosensitizer followed by local irra- greater than 80% of patients present at an unresectable 11 diation with laser therapy. The use of PDT for pallia- stage, with a median survival time of 3-6 months from 15 tion of bile-duct tumors has produced promising re- the time of diagnosis. These patients require palliative sults. Several studies conducted in Europe and the management. United States have shown that PDT produces a Surgical decompression of the biliary tract involves a marked improvement in the symptoms of cholestasis, hepatico-jejunostomy, which has a 30 day post-operative survival, and quality of life. This chapter summarizes mortality rate between 7% and 24%.16-19 Recovery time is the principle of PDT, the technique employed, and the a limiting factor in quality of life improvement in a ma- published experience regarding PDT for cholangio- jority of patients who undergo surgery.20-22 Presently, carcinoma. (Gut Liver 2010;4(Suppl. 1):S62-66) biliary decompression is most frequently accomplished through endoscopic biliary stent placement. This has been Key Words: Cholangiocarcinoma; Photodynamic thera- shown to relieve obstructive jaundice, but has not been py; Biliary cancer shown to improve survival.11 The addition of chemo- therapy to biliary decompression has been largely un- INTRODUCTION successful.23 Various chemotherapeutic agents have been studied with overall minimal improvement in survival.24-26 Cholangiocarcinoma is a malignancy that arises from The survival benefit of palliative radiation therapy is con- the epithelial cells of the biliary tree. It can affect the in- sidered controversial.10 It has been associated with an in- trahepatic and extrahepatic bile ducts and is associated creased incidence of cholangitis, gastroduodenitis, and with significant morbidity and mortality.1 Tumor for- longer hospitalizations.27-29 Concurrent chemotherapy with mation appears to be the result of an underlying chronic radiation therapy, including helical tomotherapy intensity inflammatory state of the biliary tract. There are multiple modulated radiotherapy and capecatibine, in conjunction possible predisposing conditions, which include primary with photodynamic therapy (PDT) has been shown to be sclerosing cholangitis, intrahepatic stones and choledo- well tolerated in patients with hilar cholangiocarcino- cholithiasis, choledochal cysts, liver flukes, and prior ex- ma.30,31 Wiedmann et al.32 published their results using posure to thorium dioxide.2-9 PDT as a neoadjuvant treatment for hilar cholangio- Correspondence to: Michel Kahaleh Pancreatico-Biliary Services, Digestive Health Center, Box 800708, University of Virginia Health System, Charlottesville, VA 22908-0708, USA Tel: +1-434-243-9259, Fax: +1-434-924-0491, E-mail: [email protected] DOI: 10.5009/gnl.2010.4.S1.S62 Talreja JP, et al: PDT in Cholangiocarcinoma S63 carcinoma. Seven patients were treated and underwent tients treated with PDT receive Porfimer sodium (Photo- surgery after a median period of 6 weeks (range, 3-44 frin; Axcan Pharma Inc.) at a dosage of 2 mg/kg body weeks). In all patients tumor free resection margins were weight intravenously 48 hours before laser activation. achieved with a 1-year recurrence free survival rate of Endoscopic retrograde cholangiography (ERC) is per- 83%. Neoadjuvant PDT did not increase the rate of surgi- formed using a large channel duodenoscope (TJF-140, cal complications and was well tolerated. Additionally, TJF-160, and TJF-160VF; Olympus America, Center Va- proximal obstruction of the bile ducts by malignant tissue lley, PA, USA). After cannulation into the biliary tract, a can prevent successful endoscopic stenting. Photodynamic cholangiogram is performed to help define the anatomic therapy has recently been introduced to circumvent this distribution of malignant tissue and the extent of disease problem.11 within the biliary ducts. Careful opacification of the di- lated segments is performed selectively. Next, selective PRINCIPLE OF PHOTODYNAMIC THERAPY bougie and balloon dilation of the stricture(s) to be treat- ed is performed to facilitate diffuser placement within the This therapy includes the use of, a photosensitizing malignant stricture. agent administered before the photoradiation process can Photodynamic therapy is delivered through a 3.0-m occur.33 Photofrin (porfimer sodium; Axcan Pharma Inc., length fiber with a 2.5-cm-long cylindrical diffuser at its Mont-Saint Hilaire, Canada) has a selective nature and is distal end (Pioneer Optics, Windsor Locks, CT, USA). preferentially retained by neoplastic tissue.33 At a specific The diffuser can be inserted into a 10 F sheath of a plas- wavelength of light, laser application begins the activation tic stent delivery system and placed at the level of the process by transforming the drug from its neutral ground stricture being treated.37 Alternatively, our group has state into its excited state. In the presence of oxygen, cy- been using the single operator cholangioscopy (SOC) as a totoxic radical species are formed, which destroy dys- platform to administer PDT (Spyglass; Boston Scientific, plastic cells by directly inducing apoptosis and tumor Natick, MA, USA).40 necrosis. Local vascular channels are also affected.34,35 A diode laser system (InGaAIP Laser Diode; Diomed PDT was demonstrated to reduce xenografted human Inc., Andover, MA, USA) with a maximum power output cholangiocarcinoma tumor volume by 60% in a mouse of 2,000 mW and a wavelength of 633±3 nm is used as a model.36 PDT has been shown to have a significant sur- light source. vival benefit in patients with unresectable cholangio- Photoactivation is performed at 630 nm with a light carcinoma as well as a significant improvement in the dose of 180 J/cm2, fluence of 0.250 W/cm2 and irradi- quality of life after PDT and stenting.37,38 ation time of 750 seconds. Multiple segments can be Though other photosensitizers are now available, por- treated at the discretion of the endoscopist. When tumor fimer sodium is the most studied and the only photo- length exceeds the maximal diffuser length, overlap of sensitizer approved by the FDA. treated areas should be avoided by a stepwise pull-back of the fiber under fluoroscopic guidance. Placement of endo- STAGING AND TISSUE DIAGNOSIS prostheses is performed systematically after the photo- dynamic treatment to prevent cholangitis.37 All patients must have clinical and radiological features PDT is typically repeated at 3-month intervals at which of cholangiocarcinoma. Staging can be performed by com- time all stents should be replaced; stents are exchanged puted tomography (CT) or magnetic resonance imaging earlier in the case of premature occlusion or migration to (MRI). Staging can be performed with CT and/or MRI.37 maintain optimal decompression. All patients should re- Resectability is usually defined according to the criteria of ceive peri-operative antibiotic prophylaxis. Post-operative- Vauthey and Blumgart.39 ly, patients treated with PDT are advised to remain out of Bismuth classification should be documented for all direct sunlight since Porfimer sodium may cause pro- patients.1 In our experience and others,37,40 definitive longed photosensitivity lasting 30-90 days.41 pathological diagnosis of cholangiocarcinoma is estab- lished in approximately 60% of cases.37,40 REVIEW OF THE LITERATURE TECHNIQUE There have been several uncontrolled reports that sug- gest that PDT can provide for a survival benefit (Table 1). Each patient undergoes a detailed educational process In 2003, Ortner et al.33 conducted the first randomized on PDT after which informed consent is obtained. Pa- controlled trial comparing survival between biliary stent- S64 Gut and Liver, Vol. 4, Suppl. 1, September 2010 Table 1. Table Comparing Studies Performed by Using ERCP with PDT with Photofrin Sodium for Palliation of Cholangiocarcinoma Mean PDT Median Adverse events No. of Median TB before Study Year Study type sessions survival, phototoxicity, patients and after PDT (range) mo cholangitis 41 Ortner et al. 1998 9 Single arm 18.6＞6 1.5 (1-2) 14.6 1 (11%), 0 (0%) 36 Berr et al. 2000 23 Single arm 11.2＞1.1 3 (1-5) 11.1 3 (13%), 8 (35%) 48 Rumalla et al. 2001 6 Single arm 2.7＞1.3 2.3 (1-2) ＞6 2 (33%), 2 (33%) 49 Dumoulin et al. 2003 24 Single arm 13.3＞2.6 1-2 9.9 2 (8%), 5 (21%) 33 Ortner et al. 2003 20 Randomized NA (decreased) 2.4 (1-5) 16.4 2 (10%), 5 (25%) 33 Ortner et al. 2003 31 Nonrandomized 11.8＞3.1 1.5 (1-4) 14.2 3 (10%), 6 (19%) 50 Harewood et al. 2005 8 Single arm 7.7＞1.1 2 (1-5) 9.2 2 (25%), 2 (25%) 51 Witzigmann et al. 2006 68 Single arm NA (decreased) 2 (1-6) 12 8 (12%), 38 (56%) 44 Prasad et al.
Load more

Recommended publications
  • Gastrointestinal Cancers a Multidisciplinary Approach to Screening, Diagnosis, and Treatment
    Second Annual Update on Gastrointestinal Cancers A Multidisciplinary Approach to Screening, Diagnosis, and Treatment Friday, September 27, 2013 7:00am – 4:10pm COURSE DIRECTORS K.S. Clifford Chao, MD Michel Kahaleh, MD, AGAF, FACG, FASGE P. Ravi Kiran, MBBS, MS, FRCS, FACS Tyvin Rich, MD, FACR LOCATION Columbia University Medical Center Bard Hall New York City Register Online www.columbiasurgerycme.org Second Annual Update on Gastrointestinal Cancers A Multidisciplinary Approach to Screening, Diagnosis, and Treatment OVERVIEW EDUCATIONAL OBJECTIVES This course consists of lectures, case It is intended that this Continuing presentations, and Q&A panels with Medical Education (CME) activity will lead expert faculty. The course is broken into to improved patient care. At the conclusion five sessions, each covering gastrointestinal of this activity, participants should be able to: cancer in a specific area of the GI tract. 1. Identify new technologies and modalities Speakers in each session will cover research in the screening, surveillance, and diagnosis and the latest standards of care including of relevant gastrointestinal cancers. new innovations for screening, diagnosis, and treatment modalities including radiation 2. Offer patients non-invasive, interventional, therapy, chemotherapy, and surgery. This medical, and surgical approaches in the course will increase participant familiariza- treatment of gastrointestinal cancers. tion with current guidelines and recommen- 3. Identify emerging new chemotherapy, dations, and focus on the multidisciplinary targeted therapy, and radiation therapy team involved in the care of patients with options and approaches in the treatment gastrointestinal cancers. of gastrointestinal cancers. IDENTIFIED PRACTICE GAP/ 4. Apply their enhanced understanding of EDUCATIONAL NEEDS the benefits of the multidisciplinary approach to the screening, diagnosis, Gastrointestinal cancers include several treatment, and palliation of patients with malignancies, including those of the gastrointestinal cancers.
    [Show full text]
  • Practice Patterns and Use of Endoscopic Retrograde
    Practice patterns and use of endoscopic retrograde cholangiopancreatography in the management of recurrent acute pancreatitis Qiang Cai, Emory University Field Willingham, Emory University Steven Keilin, Emory University Vaishali Patel, Emory University Parit Mekaroonkamol, Emory University JB Reichstein, Duke University S Dacha, Emory University Journal Title: Clinical Endoscopy Volume: Volume 53, Number 1 Publisher: (publisher) | 2019-01-01, Pages 73-81 Type of Work: Article Publisher DOI: 10.5946/ce.2019.052 Permanent URL: https://pid.emory.edu/ark:/25593/vhjfb Final published version: http://dx.doi.org/10.5946/ce.2019.052 Accessed September 27, 2021 7:02 AM EDT ORIGINAL ARTICLE Clin Endosc 2020;53:73-81 https://doi.org/10.5946/ce.2019.052 Print ISSN 2234-2400 • On-line ISSN 2234-2443 Open Access Practice Patterns and Use of Endoscopic Retrograde Cholangiopancreatography in the Management of Recurrent Acute Pancreatitis Jonathan B. Reichstein1, Vaishali Patel2, Parit Mekaroonkamol2, Sunil Dacha2, Steven A. Keilin2, Qiang Cai2 and Field F. Willingham2 1Department of Medicine, Duke University, Durham, NC, 2Division of Digestive Disease, Department of Medicine, Emory University, Atlanta, GA, USA Background/Aims: There are conflicting opinions regarding the management of recurrent acute pancreatitis (RAP). While some physicians recommend endoscopic retrograde cholangiopancreatography (ERCP) in this setting, others consider it to be contraindicated in patients with RAP. The aim of this study was to assess the practice patterns and clinical features influencing the management of RAP in the US. Methods: An anonymous 35-question survey instrument was developed and refined through multiple iterations, and its use was approved by our Institutional Review Board.
    [Show full text]
  • Interventional Innovations in Digestive Care to Receive the Negotiated Group Rate
    The First Annual Peter D. Stevens Course on Interventional Innovations in Digestive Ca re Special Sessions: Hands-on Animal Tissue Labs, Live OR & Interventional Cases April 2 6–27, 2012 New York City Program Co-Directors: Michel Kahaleh, MD, AGAF, FACG, FASGE Robbyn Sockolow, MD, AGAF Marc Bessler, MD, FACS Jeffrey Milsom, MD, FACS, FACG www.gi-innovations.org Endorsed by This course is endorsed by the American Society for Endorsed by the Gastrointestinal Endoscopy AGA Institute Interventional Innov ations in Digestive Ca re n Overall Goals This two day course will inform participants of the latest innovations for the management of gastrointestinal diseases and disorders, and will offer a unique opportunity to learn more about the current trends in interventional endoscopic and surgical procedures. Internationally recognized faculty will address issues in current clinical practice, compli - cations and pitfalls of newer technologies, and the evolution of the field. Using a systems- based approach, the format will cover all major areas of digestive care and treatment options. Attendee participation and interaction will be emphasized and facilitated through Q & A sessions, live OR and interactive case presentations, hands-on animal tissue labs and meet the professor break-out sessions. n Learning Objectives • Understand endoscopic necrosectomy • Understand the use of ablation • Increase knowledge of the latest therapy for bile duct cancer innovations in minimally invasive • Learn the latest advances in techniques in bariatrics endoscopic
    [Show full text]
  • Endoscopic Ultrasound
    CLINICAL GASTROENTEROLOGY Series Editor George Y. Wu University of Connecticut Health Center, Farmington, CT, USA For further volumes: http://www.springer.com/series/7672 Endoscopic Ultrasound Edited by VANESSA M. SHA M I , MD Director of Endoscopic Ultrasound University of Virginia Health System Digestive Health Center, USA and MICHEL KAHALEH , MD Director of Pancreatico-Biliary Services University of Virginia Health System Digestive Health Center, USA Editors Vanessa M. Shami, MD Michel Kahaleh, MD Associate Professor of Medicine Associate Professor of Medicine Director of Endoscopic Ultrasound Director of Pancreatico-Biliary Services Digestive Health Center Digestive Health Center University of Virginia Health System University of Virginia Health System Charlottesville, VA, USA Charlottesville, USA [email protected] [email protected] ISBN 978-1-60327-479-1 e-ISBN 978-1-60327-480-7 DOI 10.1007/978-1-60327-480-7 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2010930043 © Springer Science+Business Media, LLC 2010 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.
    [Show full text]
  • Stents for the Gastrointestinal Tract and Nutritional Implications
    NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #46 Carol Rees Parrish, R.D., M.S., Series Editor Stents for the Gastrointestinal Tract and Nutritional Implications Michelle Loch Michel Kahaleh Endoscopic stenting of many sites along the gastrointestinal tract is used successfully for palliation of malignant or benign obstructions. These obstructions may be the result of primary gastrointestinal tumors invading the lumen, tumors of another primary site causing external compression or in some instance benign diseases secondary to various inflammatory processes. Stenting of the gastrointestinal tract has been commonly per- formed either by interventional radiologists with the use of fluoroscopy, or by gas- troenterologists endoscopically, with or without fluoroscopic guidance. Their efficacy can be measured by resolution of obstruction or symptom improvement. The current literature shows that endoscopic stenting have acceptable success and complication rates and might be considered as first-line therapy in centers offering expertise in inter- ventional endoscopy. The techniques, efficacy and complication of stenting will be dis- cussed. Nutritional guidelines will also be provided based on our institutions practice. INTRODUCTION most current literature (Table 1) (4–9). Common causes ndoscopy within the last two decades has encom- of stent requirement to preserve nutritional status passed many interventional procedures allowing include esophageal, duodenal, biliary and colonic Ethe treatment of multiple conditions of the upper obstruction;
    [Show full text]
  • Endoscopic Palliation for Pancreatic Cancer
    Cancers 2011, 3, 1947-1956; doi:10.3390/cancers3021947 OPEN ACCESS cancers ISSN 2072-6694 www.mdpi.com/journal/cancers Review Endoscopic Palliation for Pancreatic Cancer Mihir Bakhru 1, Bezawit Tekola 2 and Michel Kahaleh 1,2,* 1 Division of Gastroenterology and Hepatology, University of Virginia, PO Box 800708, Charlottesville, VA 22908, USA; E-Mail: [email protected] (M.B.) 2 Division of Medicine, University of Virginia, PO Box 800708, Charlottesville, VA 22908, USA; E-Mail: [email protected] (B.T.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-434-243-9259; Fax: +1-434-924-0491. Received: 1 March 2011; in revised form: 1 April 2011 / Accepted: 1 April 2011 / Published: 13 April 2011 Abstract: Pancreatic cancer is devastating due to its poor prognosis. Patients require a multidisciplinary approach to guide available options, mostly palliative because of advanced disease at presentation. Palliation including relief of biliary obstruction, gastric outlet obstruction, and cancer-related pain has become the focus in patients whose cancer is determined to be unresectable. Endoscopic stenting for biliary obstruction is an option for drainage to avoid the complications including jaundice, pruritus, infection, liver dysfunction and eventually failure. Enteral stents can relieve gastric obstruction and allow patients to resume oral intake. Pain is difficult to treat in cancer patients and endoscopic procedures such as pancreatic stenting and celiac plexus neurolysis can provide relief. The objective of endoscopic palliation is to primarily address symptoms as well improve quality of life. Keywords: pancreatic adenocarcinoma; biliary obstruction; gastric outlet obstruction; endoscopy; stents; palliation 1.
    [Show full text]
  • Management of Benign and Malignant Pancreatic Duct Strictures
    REVIEW Clin Endosc 2018;51:156-160 https://doi.org/10.5946/ce.2017.085 Print ISSN 2234-2400 • On-line ISSN 2234-2443 Open Access Management of Benign and Malignant Pancreatic Duct Strictures Enad Dawod and Michel Kahaleh Division of Gastroenterology and Hepatology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY, USA The diagnosis and management of pancreatic strictures, whether malignant or benign, remain challenging. The last 2 decades have seen dramatic progress in terms of both advanced imaging and endoscopic therapy. While plastic stents remain the cornerstone of the treatment of benign strictures, the advent of fully covered metal stents has initiated a new wave of interest in calibrating the pancreatic duct with fewer sessions. In malignant disease, palliation remains the priority and further data are necessary before offering systematic pancreatic stenting. Clin Endosc 2018;51:156-160 Key Words: Pancreatic ducts; Pancreas; Fully covered metal stent; Cholangiopancreatography, endoscopic retrograde; Endosonography INTRODUCTION giopancreatography (ERCP) as the method of choice in ob- taining tissue specimen, as it is associated with a higher suc- Pancreatic duct stricture is a common problem that is asso- cess rate and fewer post-procedural complications.4 Pancreatic ciated with various etiologies. Benign etiologies include brushing should be employed in the absence of a definitive chronic pancreatitis, recurrent acute pancreatitis, trauma, sur- mass on imaging.3 Furthermore, repeat EUS has been shown gical complications, and pseudocysts. Pancreatic strictures can to improve diagnostic yield in the case of continued suspicion also be a manifestation of malignancy.1,2 The diagnosis and of cancer and to increase the sensitivity of pancreatic mass treatment of pancreatic strictures have proven challenging for detection in the setting of chronic pancreatitis.4,5 Confocal physicians.
    [Show full text]
  • Stent Placement As a Bridge to Surgery in Malignant Biliary Obstruction (Pancreatic Cancer, Distal Bile Duct Cancer, and Hilar Tumors)
    Gastrointest Interv 2015; -:1–6 Contents lists available at ScienceDirect Gastrointestinal Intervention journal homepage: www.gi-intervention.org Invited Review Article Stent placement as a bridge to surgery in malignant biliary obstruction (pancreatic cancer, distal bile duct cancer, and hilar tumors) Mario Rodarte-Shade, Michel Kahaleh* abstract Preoperative biliary drainage (PBD) has been a matter of controversy for years. It was initially aimed to improve the clinical status of patients with malignant obstructive jaundice prior to surgery. However, its efficacy and safety have not been proven by randomized controlled trials. Most drawbacks of PBD are related to the increase in procedure-related adverse events and inappropriate biliary decompression. Current trends in PBD show that using self- expanding metallic stents (SEMSs) may reduce the high incidence of stent-related complications with improved outcomes. The aim of this study was to review the current literature regarding PBD in patients with resectable distal pancreaticobiliary and hilar tumors. Copyright Ó 2015, Society of Gastrointestinal Intervention. Published by Elsevier. All rights reserved. Keywords: distal bile duct cancer, hilar tumor, malignant biliary obstruction, pancreatic cancer, preoperative biliary drainage Introduction review the existing literature concerning the use of PBD in patients with resectable distal pancreaticobiliary malignancies. Preopera- Malignant biliary obstruction encompasses a group of neo- tive biliary drainage in hilar tumor is also discussed separately. plasms that compromise bile duct flow and clinically presents with obstructive jaundice. Obstruction can be anatomically classified as Pathophysiology of biliary obstruction “distal” or “proximal.” Proximal bile duct obstruction refers to hilar bile duct cholangiocarcinomas (i.e., Klatskin tumors), whereas Biliary obstruction and cholestasis has several deleterious distal bile duct obstruction refers to periampullary tumors.
    [Show full text]
  • Diagnosis of Distal Cholangiocarcinoma After the Removal of Choledocholithiasis
    Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2012, Article ID 396869, 5 pages doi:10.1155/2012/396869 Clinical Study Diagnosis of Distal Cholangiocarcinoma after the Removal of Choledocholithiasis Yasuhiro Ito, 1 Takeshi Kenmochi, 1 Tomohisa Egawa,1 Shinobu Hayashi,1 Atsushi Nagashima,1 and Yuko Kitagawa2 1 Department of Surgery, Saiseikai Yokohamashi Tobu Hospital, 3-6-1 Shimosueyoshi, Tsurumi-ku, Yokohama-shi, Kanagawa 230-8765, Japan 2 Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan Correspondence should be addressed to Yasuhiro Ito, [email protected] Received 6 August 2012; Revised 16 October 2012; Accepted 18 October 2012 Academic Editor: Michel Kahaleh Copyright © 2012 Yasuhiro Ito et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background and Aim. Distal cholangiocarcinoma associated with choledocholithiasis has not been reported, and the causal relationship remains to be established. We evaluated diagnosis of distal cholangiocarcinoma diagnosed after the removal of choledocholithiasis. Patients and Methods. We assigned 9 cases of cholangiocarcinoma with choledocholithiasis to Group A. As a control group, 37 patients with cholangiocarcinoma without choledocholithiasis were assigned to Group B. Results. Abdominal pain at admission is the only significant difference between Group A and Group B (P = 0.001). All patients in Group A had gall bladder stones, compared with 7 patients (19%) in Group B (P<0.01). Of the 9 patients in Group A, endoscopic retrade cholangiopancreatography (ERCP) detected normality in 2 patients (22%) and abnormalities in 7 patients (78%).
    [Show full text]
  • Advanced-Endoscopy-Brochure.Pdf
    Advanced Endoscopy Services Division of Gastroenterology & Hepatology Clinical Academic Building, Fifth Floor 125 Paterson Street New Brunswick, NJ 08901 Phone: 732-235-7784 Cutting-edge techniques, groundbreaking research for a Our practice is a proud part of Rutgers Health , the clinical arm of Rutgers, The State University Advanced range of gastrointestinal issues of New Jersey. Rutgers Health is the most comprehensive academic From disease diagnosis to novel therapies health care provider in New Jersey, offering a Endoscopy breadth of accessible clinical care throughout the for treatment, our expert team of specialists state supported by the latest in medical research uses advanced and interventional endoscopic and education. Rutgers Health connects health techniques to meet the needs of individuals care providers across disciplines, including doctors, Services nurses, dentists, physician assistants, pharmacists, with a variety of gastrointestinal disorders, social workers, and behavioral health and addiction from gallstones to the most complex cancers professionals, with a single focus: helping people of the gastrointestinal tract. We provide and populations get well and stay well by delivering consistent, coordinated, value-based health care. minimally invasive alternatives to surgical or interventional radiology procedures, focusing on improved care and early detection and treatment of these conditions. Our dedicated, state-of-the-art endoscopy suite enables our specialists to easily Rutgers Health complies with applicable federal civil rights laws and integrate cutting-edge technology as they does not discriminate on the basis of race, color, national origin, age, disability or sex. Rutgers Health does not exclude people or treat perform the full range of highly advanced them differently because of race, color, national origin, age, disability or sex.
    [Show full text]
  • Study Protocol, Statistical Analysis Plan, and Informed
    COMIRB 19-0402 PI: Raj Shah Version Date: 8/12/19 1 Per-oral Pancreatoscopy-guided Lithotripsy vs. Extracorporeal Shock Wave Lithotripsy For Treating Symptomatic Main Pancreatic Duct Stones in Chronic Pancreatitis: A Multicenter Randomized Clinical Trial Contents Synopsis ..................................................................................................................................................................... 2 List of Abbreviations .................................................................................................................................................. 3 Study Protocol Including Research Questions/Hypothesis, Risks, and Benefits ................................................. 4-8 Research Questions and Hypothesis ..................................................................................................................... 4-5 Basic Design of the Study .................................................................................................................................... 5-8 Subject Inclusion and Exclusion Criteria ................................................................................................................. 7 Standard of Care/Research Procedure ...................................................................................................................... 9 Subject and Study Stopping Criteria ...................................................................................................................9-10 Data Collection Tool .............................................................................................................................................
    [Show full text]
  • (Cellvizio) Confocal Laser Endomicroscopy in Gastroenterology
    Review articles Utility of Probe-based (Cellvizio) Confocal Laser Endomicroscopy in Gastroenterology Elías Alfonso Forero Piñeros, MD,1 Héctor José Cardona, MD,2 Kunal Karia, MD,3 Amrita Sethi, MD,4 Michel Kahaleh, MD.5 1 Gastroenterologist and Chief of Gastroenterology and Abstract Endoscopy at the Central Police Hospital in Bogota, Colombia Probe based confocal laser endomicroscopy (Cellvizio Mauna Kea, Paris) is a new technology that allows per- 2 Gastroenterologist and Chief of Gastroenterology formance of histological analysis (optical biopsy) during any endoscopic procedure. This improves diagnosis and Hospital Simon Bolivar and GastroinvestSAS in and helps define the treatment needed for multiple digestive diseases. Its utility for diseases that are difficult Bogota, Colombia 3 Internist and Fellow in Endoscopy at Presbyterian to diagnose such as indeterminate biliary strictures and pancreatic cystic neoplasms is noteworthy. Early and Hospital and Weill Cornell Medical College at Cornell accurate diagnoses can be very difficult with currently available techniques, but they are exactly what are University in Ithaca, New York USA needed to determine whether or not expensive surgical treatments with great potential morbidity, for example 4 Gastroenterologist and interventional endoscopist at Columbia University in New York, New York USA the Whipple procedure, need to be performed. This review looks at the contribution that this technology can 5 Gastroenterologist, interventional endoscopist, Chief make in our country where it is now available for the diagnosis and study of digestive diseases. of Endoscopy and Professor of Clinical Medicine at Weill Cornell Medical College in Ithaca, New York USA Keywords ......................................... Confocal laser endomicroscopy, gastrointestinal cancer, early detection. Received: 08-09-14 Accepted: 21-07-15 Gastrointestinal cancer contributes significantly to ove- Neoplastic changes are usually accompanied by an rall cancer morbidity and mortality rates.
    [Show full text]